Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation × Thyrotropin Alfa × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 3 Differentiated Thyroid Cancer 3 Adenocarcinoma, Follicular 3 Thyroid Neoplasms 1 Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1 Low Risk Differentiated Thyroid Cancer 1 DTC - Differentiated Thyroid Cancer 1

Interventions

trametinib 1 dabrafenib 1 Thyrotropin Alfa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03244956 2021-09-28

MERAIODE

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown

EndocrineHead & Neck

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡